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Jonathan N.W.N. Barker3, Jane Worthington2 and Christopher E.M. Griffiths1
Methotrexate, an inexpensive first-line systemic therapy for moderate-to-severe psoriasis, is limited in its use by
unpredictable efficacy and toxicity. This study was designed to test the hypothesis that single-nucleotide
polymorphisms (SNPs) in methotrexate transmembrane transporters and adenosine receptors are associated
with efficacy and/or toxicity of the drug. DNA was collected from 374 patients with chronic plaque psoriasis who
had been treated with methotrexate. Phenotypic data on efficacy and toxicity were available. Haplotype tagging
SNPs (r240.8) across the relevant genes, with a minor allele frequency of45%, were selected from the HAPMAP
phase II data. SNPs within the efflux transporter genes ABCC1 (ATP-binding cassette, subfamily C, member 1)
and ABCG2 (ATP-binding cassette, subfamily G, member 2) are associated with good response to methotrexate
therapy in patients with psoriasis; the former gene was also associated with the onset of toxicity. With one SNP
in ABCC1, rs246240, the carriage of two copies of allele 1 gives an odds ratio of 2.2 (95% confidence interval:
1.3–3.6; P¼ 0.001) for developing toxicity to methotrexate. These data indicate that knowledge of SNPs in genes
relevant to methotrexate efflux may be important in selecting patients suitable for this therapy.
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INTRODUCTION
Psoriasis, a common inflammatory skin disease affecting
2% of the population, produces significant morbidity and
impaired quality of life (Griffiths and Barker, 2007). Most
patients can be treated with topical preparations, but
approximately 15% require systemic therapy. Biological
therapies such as etanercept, efalizumab, and infliximab are
novel treatment options for psoriasis, but their cost, approxi-
mately d10,000 ($20,000) per annum, and long-term safety
issues may limit their use.
Methotrexate is a low-cost, d55 ($110) per annum, first-
line systemic therapy for psoriasis; however, its use is limited
by interindividual variation in efficacy and the development
of significant hepatotoxicity and gastrointestinal symptoms.
Although many patients benefit from this effective treatment,
a significant number are exposed to a potentially dangerous
therapy from which they may derive no benefit. Pharmaco-
genetics, a term first used by Vogel in 1959 (Vogel, 1959) to
describe how genetic variations influence individual
response to drugs, may provide a mechanism for improved
targeting of therapies such as methotrexate. The only
previous methotrexate pharmacogenetic study performed in
a cohort of psoriasis patients (n¼ 202) showed associations
between a polymorphism in the methotrexate influx trans-
porter solute carrier family 19, member 1 (SLC19A1, protein
product name reduced folate carrier (RFC)), and in an
enzyme of the pyrimidine pathway, thymidylate synthase,
and methotrexate-induced toxicity (Campalani et al., 2007).
Studies in patients with rheumatoid arthritis treated with
methotrexate have suggested that genetic variation within
genes of the folate, pyrimidine, and purine pathways may
influence both the efficacy and toxicity of this drug (van Ede
et al., 2001; Urano et al., 2002; Kumagai et al., 2003;
Wessels et al., 2006). However, these studies were typically
in small cohorts of patients and generated variable results
and/or focused on isolated polymorphisms within single
genes relevant to methotrexate metabolism (van Ede et al.,
2001; Urano et al., 2002; Kumagai et al., 2003; Wessels
et al., 2006; Campalani et al., 2007).
Although the mechanism of action of methotrexate in
psoriasis is not fully understood, it is clear that genetic
variation in genes involved in methotrexate transmembrane
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transport and mediation of the anti-inflammatory effects
via adenosine receptors could influence both efficacy
and toxicity of the drug. Previously, these factors have been
neglected, with the focus of pharmacogenetic studies pre-
dominantly on genes coding for enzymes—pharmacokinetic
factors (van Ede et al., 2001; Urano et al., 2002; Kumagai
et al., 2003; Wessels et al., 2006). There is now an
appreciation that genetic variation leading to alterations in
transporters and receptors (pharmacodynamic factors) may
be equally as important as pharmacokinetic factors. We have
completed a systematic screen across five key genes (Figure 1)
involved in pharmacodynamic factors related to methotrex-
ate, in patients with psoriasis. To the best of our knowledge,
this is the first such study to look at the effects of the two
efflux transporters: ATP-binding cassette, subfamily C,
member 1 (ABCC1) and ATP-binding cassette, subfamily G,
member 2 (ABCG2); and the adenosine receptors A1
(ADORA1) and A2a (ADORA2a). Considerable variation
exists across all genes involved in methotrexate metabolism.
By utilizing haplotype tagging single-nucleotide polymor-
phisms (SNPs), we have investigated predictors of outcome to
methotrexate therapy across each relevant gene in the largest
patient cohort studied to date.
RESULTS
Patients with chronic plaque psoriasis (n¼ 374; female
patients 61%; mean age of onset 24 years, range: 1–67 years)
treated with methotrexate were recruited into the study.
Analysis of treatment response was based on 372 patients
who had completed at least 3 months of therapy, of which
250 were defined as ‘‘responders’’ and 80 as ‘‘non-
responders’’. Adverse events had occurred in 177 patients
while on methotrexate, and 189 patients had ‘‘no adverse
event’’. Subgroup analysis of toxicity was recorded in 283
patients for hepatotoxicity and 288 patients for gastrointesti-
nal toxicity. Hepatotoxicity and gastrointestinal toxicity
occurred in 65 and 79 patients, respectively. As only three
patients within the cohort developed bone marrow toxicity,
this was not analyzed as a separate subgroup.
Data were obtained for 84 SNPs from 5 genes in the
patient cohort, with a genotype success rate of 480%.
Significant genotypic associations (Po0.05; w2 test for trend)
were found between SNPs in the two efflux transporters,
ABCC1 and ABCG2, and response to methotrexate (Table 1),
whereas significant genotypic associations (Po0.05; w2 test
for trend) were found in SNPs of three genes, ABCC1,
SLC19A1, and ADORA2a, and development of methotrexate-
related toxicity (Table 2).
Efficacy
Three of the 40 SNPs in the gene ABCC1 (Table 1; Figure 2)
were associated with response to methotrexate. SNP rs35592
(intron 9) was the most significant (P¼0.008; w2 test for
trend), with the risk inferred by the carriage of two copies of
allele 1 giving an odds ratio (OR) of 2.2 (95% confidence
interval (CI): 1.2–4.1; P¼ 0.005) for responders to methotrex-
ate. Two other SNPs, rs2238476 (intron 23) and rs28364006
(exon 28), were less significant on w2 test for trend (P¼0.02
in both cases), with response to methotrexate being
associated with carriage of the major allele in both cases.
Two of the 12 SNPs, rs17731538 and rs13120400 (introns
2 and 9), in the gene ABCG2 were associated with clinical
response to methotrexate with w2 test for trends of P¼0.007
and P¼0.03, respectively. The risk inferred by the carriage of
two copies of allele 1 gave an OR of 2.1 (95% CI: 1.1–3.7;
P¼0.01) for methotrexate responders in the case of
rs17731538, whereas the carriage of allele 2 gave an OR of
1.8 (95% CI: 1.0–3.5; P¼0.05) for clinical responders to
methotrexate in the case of rs13120400.
No positive genotypic associations (Po0.05; w2 test for
trend) were detected with methotrexate responders in the other
three genes tested (SLC19A1, ADORA1, and ADORA2a).
Toxicity
Polymorphisms in ABCC1 were found to be important in the
development of adverse events in patients treated with
methotrexate (Table 2; Figure 2) with evidence of associa-
tions to six SNPs. Five of the SNPs (rs11075291, rs1967120,
rs3784862, rs246240, and rs3784864) had an r2 correlation
between 0.43 and 0.8. Carriage of the inferred haplotype
comprising the risk allele for each of the five associated SNPs
was significantly associated with the development of adverse
events (P¼ 0.001), suggesting that there is a functionally
important polymorphism residing on this haplotype. The
two most significant associations were with individual SNPs
rs246240 (P¼0.0006; w2 test for trend) and rs3784862
(P¼0.002; w2 test for trend). In the case of rs246240, the
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Figure 1. Methotrexate metabolic pathway. Methotrexate is transported
into the cell via the folate carrier (SLC19A1). It can be actively transported
out of the cell by the ATP-binding cassette transporters, ABCC1 and ABCG2.
Within the cell, it undergoes polyglutamation (activation) before directly and
indirectly inhibiting enzymes of the folate, purine, and pyrimidine pathways.
Its final mechanism in psoriasis is likely to be mediated via adenosine
receptors. The key transporters and receptors selected for study are
highlighted in red. ABCC1, ATP-binding cassette, subfamily C, member 1;
ABCG2, ATP-binding cassette, subfamily G, member 2; SLC19A1, solute
carrier family 19, member 1; GGH, g-glutamyl hydrolase; FPGS,
folylpolyglutamate synthase; ADORA1, adenosine receptor A1; ADORA2a,
adenosine receptor A2a.
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carriage of two copies of allele 1 gave an OR of 2.2 (95% CI:
1.3–3.6; P¼0.001), whereas with rs3784862 the carriage of
two copies of allele 1 gave an OR of 2.1 (95% CI: 1.3–3.5;
P¼0.002) for the onset of toxicity to methotrexate. The
observed associations do not appear to be specific to the
development of hepatic or gastrointestinal toxicity, as
evidence for the most strongly associated SNP, rs246240,
was found in both subgroups (w2 test for trend: gastrointesti-
nal, P¼ 0.006 and hepatic, P¼ 0.01) despite the smaller
sample sizes.
SNP rs2238476 indicated an independent association
(P¼0.01; w2 test for trend) with the carriage of two copies
of allele 1 and onset of toxicity with an OR of 2.49 (95% CI:
1.1–6.0; P¼ 0.01).
Two SNPs, rs1051266 (SLC19A1) and rs5760410 (ADOR-
A2a), were weakly associated with the onset of toxicity both
with a w2 test for trend of P¼0.03.
DISCUSSION
In this large and comprehensive study of patients with
chronic plaque psoriasis, we found genotypic associations
between SNPs in ABCC1 and ABCG2 and methotrexate
efficacy and SNPs in ABCC1, SLC19A1, and ADORA2a and
methotrexate toxicity. To the best of our knowledge, this is
Table 1. Positive associations of SNPs in the five genes studied with response to methotrexate in patients with
psoriasis
Genotype frequencies, responder Genotype frequencies, non-responder Trend test
Gene rs number 1_1 (%) 1_2 (%) 2_2 (%) 1_1 (%) 1_2 (%) 2_2 (%) P-value
ABCC1 rs35592 134 (61) 68 (31) 17 (8) 26 (41) 29 (46) 8 (13) 0.008
ABCC1 rs2238476 218 (92) 19 (8) 0 (0) 61 (84) 11 (15) 1 (1) 0.02
ABCC1 rs28364006 209 (91) 21 (9) 0 (0) 73 (99) 1 (1) 0 (0) 0.02
ABCG2 rs13120400 100 (48) 84 (40) 24 (12) 37 (63) 19 (32) 3 (5) 0.03
ABCG2 rs17731538 179 (77) 52 (22) 3 (1) 46 (61) 26 (35) 3 (4) 0.007
ABCC1, ATP-binding cassette, subfamily C, member 1; ABCG2, ATP-binding cassette, subfamily G, member 2; SNP, single-nucleotide polymorphism.
Percentage of each genotype frequency is shown in parentheses.
Major allele=1.
Minor allele=2.
Table 2. Positive associations of SNPs in the five genes studied with adverse events in patients with psoriasis treated
with methotrexate
Genotype frequencies, toxicity Genotype frequencies, no toxicity Trend test
Gene rs number 1_1 (%) 1_2 (%) 2_2 (%) 1_1 (%) 1_2 (%) 2_2 (%) P-value
ABCC1 rs2238476 147 (94) 10 (6) 0 (0) 153 (85) 25 (14) 1 (1) 0.01
ABCC1 rs3784864 46 (30) 76 (51) 28 (19) 43 (25) 77 (45) 52 (30) 0.03
ABCC1 rs246240 131 (80) 33 (20) 0 (0) 116 (65) 57 (32) 6 (3) 0.0006
ABCC1 rs3784862 91 (69) 34 (26) 7 (5) 80 (51) 58 (37) 18 (12) 0.002
ABCC1 rs1967120 87 (54) 65 (40) 10 (6) 79 (45) 70 (40) 27 (15) 0.01
ABCC1 rs11075291 59 (40) 70 (48) 18 (12) 51 (31) 76 (45) 40 (24) 0.008
ADORA2a rs5760410 47 (29) 81 (51) 32 (20) 38 (21) 91 (51) 51 (28) 0.03
SLC19A1 rs1051266 46 (31) 68 (46) 35 (23) 66 (40) 77 (46) 24 (14) 0.03
ABCC1, ATP-binding cassette, subfamily C, member 1; ADORA2a, adenosine receptor A2a; SCL19A1, solute carrier family 19, member 1; SNP, single-
nucleotide polymorphism.
Percentage of each genotype frequency is shown in parentheses.
Major allele=1.
Minor allele=2.
Exon
0
Introns 9, 23, exon 28
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Adverse event
Figure 2. Summary of associations between MTX therapy and adverse events
(purple arrows) and efficacy (orange arrows) detected across the gene
ABCC1.
www.jidonline.org 1927
RB Warren et al.
Methotrexate Pharmacogenetics
the first study to show the potential of genetic variation across
the efflux transporters (ABCC1 and ABCG2) and adenosine
receptors (ADORA2a) in influencing the response to metho-
trexate therapy for any indication. Furthermore, by utilizing
haplotype tagging SNPs, we have comprehensively screened
sites across each selected gene for potential associations with
outcomes of treatment with methotrexate.
Three SNPs in ABCC1—rs28364006, rs2238476, and
rs35592—appear to influence the efficacy of methotrexate.
Interestingly, the first of these SNPs is located within a coding
region (exon 28) of the gene (Choudhuri and Klaassen, 2006),
which plays a role in the production of one of the nucleotide-
binding domains, thereby allowing efficient ATP hydrolysis
(Hyde et al., 1990). Given that this SNP causes an amino-acid
change from alanine to threonine, it is biologically plausible
for it to have a significant effect on protein function by
interference with ATP binding. We postulate that such an
SNP-related decrease in the activity of this ATP-dependent
efflux pump could result in intracellular retention of
methotrexate and polyglutamated methotrexate. This process
is cytotoxic and, if involving T cells, would enhance efficacy.
Six SNPs in ABCC1 (rs11075291, rs1967120, rs3784862,
rs246240, rs3784864, and rs2238476) had a significant
association with the onset of adverse events. All intronic
with no known function the r2 correlation between five of the
six SNPs is between 0.43 and 0.8, suggesting that all are
simply showing one effect from a common site within the
ABCC1 gene. These SNPs define a haplotype on which
resides an as yet unknown functionally important polymorph-
ism. Sequencing of this region of the gene and further
association studies will be required to identify the mechanism
by which this effect is mediated. It is likely that loss of
function, secondary to a functional polymorphism, in the
energy-dependent efflux process leads to elevated intracel-
lular levels of methotrexate and subsequent toxicity.
SLC19A1 plays an important role in transport of metho-
trexate into cells. A common SNP, rs1051266 (G80A), the
exact function of which remains unclear, is associated with
clinical response to methotrexate in patients with rheumatoid
arthritis (Dervieux et al., 2004). We found that this SNP
(rs1051266) was associated with the onset of adverse events,
as was the case in the only previous study in psoriasis patients
(Campalani et al., 2007). It is important to note that 194
patients within this cohort are the same as those studied in
Campalani’s study. This is the only marker that overlaps
between the two studies.
To our knowledge, no other studies have examined
whether genetic variation across the genes ADORA1 and
ADORA2a affects outcome to treatment with methotrexate.
We have found that one SNP (rs5760410) in ADORA2a is
weakly associated with methotrexate-induced toxicity.
There are limitations to this study. Phenotypic data were
collected in a retrospective manner; thereby, objective
assessment of clinical progress was not possible. Ideally,
future studies should be performed in a prospective cohort of
patients. Furthermore, we have carried out multiple tests
(n¼84) on markers that are correlated to varying degrees and
there is no accepted method to appropriately correct these
data. Applying the Bonferroni correction for 84 tests is clearly
overly stringent, and the majority of significant associations
are lost. However, using this stringent correction, the
association with rs246240 and methotrexate toxicity remains
(P¼0.05). This correction may well have generated false-
negative results; therefore, validation of these associations
requires investigation in independent cohorts of psoriasis
patients.
This methotrexate pharmacogenetic study is one of the
largest in terms of patient numbers (n¼ 374) and most
comprehensive in respect of markers (n¼ 84) and genes
(n¼5) tested. We had 80% power (Po0.05) to detect
an association with a relative risk of 2.0–2.1 assuming
a dominant model, taking the minor risk allele to have
a frequency of 10%. Furthermore, in all five genes studied,
we estimate to have assessed at least 80% of the variation
described in the HAPMAP phase II data. This study has
highlighted the relative importance of genetic variation in
genes coding for transporters and receptors (pharmaco-
dynamic factors), as well as genes coding for enzymes
(pharmacokinetic factors), with the most significant associa-
tions being detected in the efflux gene ABCC1. This is in
keeping with a general trend in pharmacogenetics where
there is an increasing appreciation of the value of assessing
genetic variation in dynamic factors. An example of this
approach is typified by interindividual variation in warfarin
response in relation to polymorphisms in the vitamin K
epoxide reductase receptor (Rieder et al., 2005).
Over the last decade, it has become clear that single
polymorphisms in one gene have rarely proven to be
predictive of drug treatment outcomes. We anticipate that
the best predictive value ultimately will be derived from
combinations of polymorphisms across multiple genes
responsible for a drug’s metabolism. It is probable that
pharmacogenetic indices for commonly prescribed drugs
with a narrow therapeutic index, such as methotrexate, will
become available for patients with psoriasis. In essence,
pharmacogenetics has the potential to deliver medicines on a
personalized, cost-effective basis.
MATERIALS AND METHODS
This study adheres to the Declaration of Helsinki Principles and was
approved by the relevant local research ethics committees, and all
subjects provided written informed consent.
Adult patients with chronic plaque psoriasis who had received
methotrexate for treatment of their disease were recruited retro-
spectively from The Dermatology Centre, Hope Hospital, Manchester,
UK (n¼ 180), and St Thomas’ Hospital, London, UK (n¼ 194).
Evaluation of efficacy
Patients were stratified into two categories: (i) responders—those
with clearly documented clinical improvement, by use of the
psoriasis area and severity index (Fredriksson and Pettersson, 1978),
that is, a 475% reduction in psoriasis area and severity index from
the start of methotrexate therapy; and (ii) non-responders—those
patients who showed no clear improvement, that is, o50%
improvement in psoriasis area and severity index while on therapy.
Patients with an indeterminate response were excluded as were
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those who were not on methotrexate monotherapy. In cases where
a clear psoriasis area and severity index score was not recorded, an
explicit statement of response recorded in the clinical records was
also acceptable.
Evaluation of toxicity
The adverse effects of methotrexate were assessed by clinical
records.
1. Hepatotoxicity: Alanine transaminase three times the upper limit
of normal on two consecutive outpatient visits and/or serum
level of amino-terminal propeptide of type III procollagen
elevated above 4.2 mg l1 on three occasions in 1 year or
8.0mg l1 on one occasion and/or liver biopsy histological
changes consistent with methotrexate hepatotoxicity.
2. Bone marrow suppression: Leukopenia (o3.0 109 l1 total
white cell count) and/or depressed hemoglobin (o90 g l1) and/
or thrombocytopenia (plateletso100 109 l1) that resolved on
cessation of methotrexate therapy.
3. Gastrointestinal toxicity: Nausea, vomiting, or diarrhea severe
enough to necessitate cessation of methotrexate (with resolution
of symptoms) or the addition of an anti-emetic.
Patients who had consumed alcohol to excess before or during
treatment, or had persistent renal dysfunction were excluded from
analysis.
Bioinformatics
To facilitate a thorough and efficient screen of the selected genes,
SNPs were located and downloaded from the public HAPMAP
phase II, October 2005 database (http://www.hapmap.org/).
Haplotype tagging SNPs (r2 threshold 40.8) were identified and
filtered through the Haploview software omitting all markers having
a minor allele frequency o5%. Details of all SNPs investigated in
the five genes are detailed in Table S1a–e.
Genotype analysis
After informed consent had been obtained, 10ml of blood was taken
from each patient. DNA was extracted from leukocytes using a
standard phenol–chloroform extraction procedure. Using Sequenom
MassARRAY technology, 84 SNPs were genotyped in five genes,
according to the manufacturer’s instructions.
Statistical analyses
The statistical software package STATA version 8.2 (StataCorp LP,
College Station, TX) was used to compare genotype frequencies
(w2 test for trend) to evaluate the association of each SNP with
responder or non-responder and the presence or absence of adverse
event: gastrointestinal toxicity and hepatotoxicity.
CONFLICT OF INTEREST
CH Smith has received speaker’s fees or consulting fees from Merck-Serono
and Wyeth. JNWN Barker has acted as a consultant to Abbott, Janssen-Cilag,
Novartis, Schering-Plough, and Wyeth and has lectured at sponsored
symposia for the above companies. He has no shares in any of the companies.
CEM Griffiths has received research grants, speaker’s fees, or consulting fees
from Abbott, Centocor, Galderma, Janssen-Cilag, Leo, Merck-Serono,
Novartis, Schering-Plough, UCB Pharma, and Wyeth all of which manufac-
ture products used for the treatment of psoriasis.
ACKNOWLEDGMENTS
RB Warren is a recipient of a Clinical Research Training Fellowship from the
Medical Research Council, UK (Grant Fellowship—G0500449), which has
funded this work. Rhodri Smith is a recipient of a Stiefel Laboratories PhD
Studentship. We thank Dr Xiayi Ke for his support with statistical analysis.
SUPPLEMENTARY MATERIAL
Table S1a. Details of the SNPs used in the ABCC1 analysis.
Table S1b. Details of the SNPs used in the ABCG2 analysis.
Table S1c. Details of the SNPs used in the ADORA1 analysis.
Table S1d. Details of the SNPs used in the ADORA2a analysis.
Table S1e. Details of SNPs used in SLC19A1 analysis.
REFERENCES
Campalani E, Arenas M, Marinaki AM, Lewis CM, Barker JNWN, Smith CH
(2007) Polymorphisms in folate, pyrimidine, and purine metabolism are
associated with efficacy and toxicity of methotrexate in psoriasis. J Invest
Dermatol 127:1860–7
Choudhuri S, Klaassen CD (2006) Structure, function, expression, genomic
organization, and single nucleotide polymorphisms of human ABCB1
(MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J
Toxicol 25:231–59
Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M et al. (2004)
Polyglutamation of methotrexate with common polymorphisms in
reduced folate carrier, aminoimidazole carboxamide ribonucleotide
transformylase, and thymidylate synthase are associated with metho-
trexate effects in rheumatoid arthritis. Arthritis Rheum 50:2766–74
Fredriksson T, Pettersson U (1978) Severe psoriasis—oral therapy with a new
retinoid. Dermatologica 157:238–44
Griffiths CEM, Barker JNWN (2007) Pathogenesis and clinical features of
psoriasis. Lancet 370:263–71
Hyde SC, Emsley P, Hartshorn MJ, Mimmack MM, Gileadi U, Pearce SR et al.
(1990) Structural model of ATP-binding proteins associated with cystic
fibrosis, multidrug resistance and bacterial transport. Nature 346:362–5
Kumagai K, Hiyama K, Oyama T, Maeda H, Kohno N (2003) Polymorphisms
in the thymidylate synthase and methylenetetrahydrofolate reductase
genes and sensitivity to the low-dose methotrexate therapy in patients
with rheumatoid arthritis. Int J Mol Med 11:593–600
Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL et al.
(2005) Effect of VKORC1 haplotypes on transcriptional regulation and
warfarin dose. N Engl J Med 352:2285–93
Urano W, Taniguchi A, Yamanaka H, Tanaka E, Nakajima H, Matsuda Y et al.
(2002) Polymorphisms in the methylenetetrahydrofolate reductase
gene were associated with both the efficacy and the toxicity of
methotrexate used for the treatment of rheumatoid arthritis, as
evidenced by single locus and haplotype analyses. Pharmacogenetics
12:183–90
van Ede AE, Laan RF, Blom HJ, Huizinga TW, Haagsma CJ, Giesendorf BA
et al. (2001) The C677T mutation in the methylenetetrahydrofolate
reductase gene: a genetic risk factor for methotrexate-related elevation
of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum
44:2525–30
Vogel F (1959) Moderne problem der humangenetik. Ergeb Inn Med U
Kinderheilk 12:52–125
Wessels JA, Kooloos WM, De JR, de Vries-Bouwstra JK, Allaart CF, Linssen A
et al. (2006) Relationship between genetic variants in the adenosine
pathway and outcome of methotrexate treatment in patients with recent-
onset rheumatoid arthritis. Arthritis Rheum 54:2830–9
www.jidonline.org 1929
RB Warren et al.
Methotrexate Pharmacogenetics
